Major surgery in a neutropenic patient undergoing allogeneic stem cell transplantation for high risk myelofibrosis.
Certain homeostatic functions are particularly important to the success of extensive surgery. For example metabolic homeostasis, inflammation and tissue repair, coagulation and immune defense against infection are all of great importance. In patients undergoing allogeneic hematopoietic stem cell transplantation (ASCT), the ability to mount adequate inflammatory responses is severely impaired. Thrombocytopenia is common making coagulation inadequate for any kind of invasive procedure, let alone extensive surgery. For this reason, abdominal surgery in neutropenic patients is associated with very high mortality rates of between 50 and 70 % [1]. Here, we describe a patient with high-risk myelofibrosis who required extensive abdominal surgery during the aplastic phase only 7 days after ASCT due to severe abdominal hemorrhage. This patient's successful recovery shows that extensive surgery is possible even during the aplastic phase after ASCT. Interestingly, we also found that radical splenectomy 7 days after stem cell transplantation did not lead to any significant loss of infused stem cells.
Center for Allogeneic Stem Cell Transplantation, B87, Karolinska University Hospital Huddinge, 14186, Stockholm, Sweden. petter.brodin@ki.se
Petter
P
Brodin
Stefan
S
Gilg
Lars
L
Lundell
Jonas
J
Mattsson
D000230:Adenocarcinoma / Q000150:complications / Q000532:radiotherapy; D004947:Esophagus / Q000601:surgery; D005743:Gastrectomy; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D005773:Gastroscopy; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D007583:Jejunum / Q000601:surgery; D008026:Ligation; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D036102:Peripheral Blood Stem Cell Transplantation; D011087:Polycythemia Vera / Q000150:complications / Q000503:physiopathology; D055728:Primary Myelofibrosis / Q000150:complications / Q000601:surgery*; D011471:Prostatic Neoplasms / Q000150:complications / Q000532:radiotherapy; D012306:Risk; D013156:Splenectomy; D013921:Thrombocytopenia / Q000209:etiology; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D014662:Vasoconstrictor Agents